"Das Immunologikum Hamburg ist ein Zentrum für Rheumatologie und klinische Immunologie mit angeschlossener Tagesklinik und Studienambulanz."

During the past decade, Rheumatologie im Struenseehaus conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Rheumatologie im Struenseehaus" are "Arthritis, Psoriatic" (1 trials) and "Rheumatoid Arthritis" (1 trials). Many other conditions were trialed in "Rheumatologie im Struenseehaus" in a lesser frequency.

Most popular intervention types in "Rheumatologie im Struenseehaus" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Filgotinib" (1 trials), "Guselkumab" (1 trials) and "IL-17i" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rheumatologie im Struenseehaus" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Rheumatologie im Struenseehaus". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Rheumatologie im Struenseehaus, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Rheumatologie im Struenseehaus, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".